On April 23, 2026, the U.S. Food and Drug Administration (FDA) updated its Voluntary Cosmetic Registration Program (VCRP) database by assigning a dedicated INCI code — PSC-2026 — to plant stem cell extracts used in cosmetics. This change requires detailed documentation of botanical species, tissue origin, culture medium composition, and passage number during registration. Skincare OEM manufacturers — especially those supplying U.S.-bound products — are now facing heightened compliance scrutiny and delayed submissions.

Event Overview

On April 23, 2026, the FDA updated the Voluntary Cosmetic Registration Program (VCRP) database to introduce a new, standalone INCI identifier — PSC-2026 — specifically for plant stem cell extracts. Under this update, registrants must submit, alongside standard cosmetic product information: (1) the full botanical name of the source plant; (2) the anatomical origin of the stem cells (e.g., meristematic tissue from shoot apices); (3) a complete list of components in the in vitro culture medium; and (4) the number of subcultures (passages) performed prior to extraction. As of the update’s implementation, three Chinese contract manufacturing organizations (CMOs) have had submissions rejected by the FDA’s online system due to incomplete or non-compliant documentation.

Industries Affected

Skincare OEM/ODM Manufacturers

These manufacturers are directly impacted because they prepare and submit VCRP registrations for finished products containing plant stem cell extracts. The new requirement adds a technical documentation layer that many lack internal expertise to compile — particularly around standardized botanical nomenclature and cell culture process transparency. Delays in registration now translate directly into shipment holds or customs clearance issues for U.S.-bound goods.

Active Ingredient Suppliers (Plant Stem Cell Extract Providers)

Suppliers must now provide traceable, auditable technical dossiers to their downstream clients — including validated species identification, harvest protocols, and full culture medium specifications. Absent such documentation, their ingredients cannot be registered under PSC-2026, limiting market access for formulations relying on these materials.

Regulatory Affairs & Compliance Service Providers

Firms offering regulatory support for cosmetic imports into the U.S. face increased workload and technical complexity. Pre-submission review now requires verification of biological sourcing and bioprocess parameters — areas previously outside standard cosmetic ingredient assessment scope. This raises demand for cross-disciplinary expertise bridging botany, cell culture, and FDA regulatory practice.

What Stakeholders Should Monitor and Do Now

Track official FDA guidance updates beyond the VCRP database entry

The current requirement is embedded in the VCRP submission interface and associated field-level validation rules. However, no formal guidance document or notice has been published in the Federal Register. Stakeholders should monitor FDA’s Cosmetics webpage and subscribe to CDER’s email alerts for any forthcoming policy clarification or Q&A release.

Review existing formulas containing plant stem cell extracts for U.S. distribution

Brands and manufacturers should identify all SKUs using such ingredients and assess whether supporting data — especially on species, tissue source, and culture conditions — is available, verifiable, and consistent with INCI naming conventions. Prioritize re-registration of high-volume or newly launched items ahead of potential enforcement follow-up.

Distinguish between regulatory signal and operational readiness

This change reflects a procedural tightening within an otherwise voluntary program. It does not constitute a ban, safety determination, or mandatory premarket approval. However, failure to comply blocks VCRP registration — which, while voluntary, remains a key expectation for FDA engagement and critical for demonstrating compliance posture during inspections or import reviews.

Initiate cross-functional alignment between R&D, procurement, and regulatory teams

Ingredient specifications must now include bioprocess metadata. Procurement teams should revise supplier questionnaires; R&D should document culture protocols in formulation records; and regulatory staff must validate consistency across spec sheets, COAs, and VCRP submissions. Internal SOPs for ingredient dossier management should be updated accordingly.

Editorial Perspective / Industry Observation

Observably, this update signals FDA’s growing attention to biologically derived cosmetic ingredients — particularly those invoking ‘stem cell’ terminology, which carries implicit functional connotations. While the VCRP remains voluntary, the introduction of a dedicated code with mandatory technical fields suggests FDA is building infrastructure to support future oversight, possibly linked to emerging concerns about adulteration, mislabeling, or unverified biological activity claims. Analysis shows this is currently a procedural refinement rather than a substantive regulatory shift — but it functions as a clear marker of evolving expectations for transparency in botanical biotechnology inputs. From an industry perspective, it underscores that ‘natural’ or ‘bioactive’ claims increasingly trigger documentation rigor comparable to pharmaceutical excipients.

Conclusion: This update does not alter the legal status of plant stem cell extracts in cosmetics, nor does it impose new safety requirements. Rather, it elevates documentation standards for traceability and process transparency within the existing voluntary registration framework. It is best understood not as an immediate barrier, but as an early indicator of how FDA may approach increasingly complex botanical biotechnologies in future regulatory actions — warranting proactive alignment, not reactive crisis response.

Source: U.S. FDA Voluntary Cosmetic Registration Program (VCRP) database update, effective April 23, 2026. Note: No accompanying Federal Register notice or guidance document has been issued as of publication. Continued observation is warranted for supplemental clarifications.